CBLPath Revenue and Competitors

Port Chester, NY USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CBLPath's estimated annual revenue is currently $34.8M per year.(i)
  • CBLPath's estimated revenue per employee is $270,000

Employee Data

  • CBLPath has 129 Employees.(i)
  • CBLPath grew their employee count by 2% last year.

CBLPath's People

NameTitleEmail/Phone
1
VP FinanceReveal Email/Phone
2
VP Quality Assurance, Regulatory and ComplianceReveal Email/Phone
3
Director DermatopathologyReveal Email/Phone
4
Director Accounts ReceivableReveal Email/Phone
5
Lab Operations Manager - Post TechnicalReveal Email/Phone
6
ManagerReveal Email/Phone
7
Manager, Client ServiceReveal Email/Phone
8
Breast PathologistReveal Email/Phone
9
FISH Cytomolecular TechnologistReveal Email/Phone
10
Senior Account ExecutiveReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$49.9M1682%N/AN/A
#2
$300.1M794-9%N/AN/A
#3
$10.2M474%N/AN/A
#4
$23.5M8732%N/AN/A
#5
$30.5M1138%N/AN/A
#6
$31.9M1189%N/AN/A
#7
$26.5M98-2%N/AN/A
#8
$4.9M26-13%N/AN/A
#9
$75.7M2554%N/AN/A
#10
$229.4M6693%$177.7MN/A
Add Company

What Is CBLPath?

CBLPath, Inc. is a leading provider of sub-specialized anatomic pathology and molecular diagnostic laboratory services. We are committed to partnering with our physician-clients to provide the best possible patient care. Founded in 1988 as Cytopath Biopsy Lab, our landmark laboratory quickly established a reputation for providing definitive diagnoses coupled with extraordinary customer service.

keywords:N/A

N/A

Total Funding

129

Number of Employees

$34.8M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CBLPath News

2022-03-22 - After living near Chernobyl, these Pitt researchers set their ...

UPMC licensed ThyroSeq from the University in 2017 and partnered with CBLPath, Inc., a branch of the Austin, Texas-based Sonic Healthcare...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$33.8M1388%N/A
#2
$31.1M1573%N/A
#3
$30.1M15915%N/A
#4
$66.2M237N/AN/A
#5
$49.5M2509%N/A